Study of Tegavivint Plus Zanzalintinib in Patients With Advanced Hepatocellular Carcinoma

Authors
Category Primary study
Registry of TrialsClinicalTrials.gov
Year 2026
The goal of this clinical trial is to evaluate the combination of zanzalintinib (XL092) and tegavivint in advanced hepatocellular carcinoma (HCC) and Wnt pathway mutations who have progressed after at least one prior line of systemic therapy and are naïve (not previously treated with) standard of care tyrosine kinase inhibitors targeting vascular endothelial growth factor signaling.
Epistemonikos ID: 44ff1a185ec7e6544539f233ad418aa37a37f0fb
First added on: Oct 17, 2026